Daunorubicin is used in combination with other approved anticancer medicines to induce remission in patients with acute non-lymphocytic leukemia (ANLL)—including myelogenous, monocytic, and erythroid leukemia—in adults. It is also used to induce remission in acute lymphocytic leukemia (ALL) in both adults and children.

Daunorubicin exhibits antimitotic and cytotoxic effects through several mechanisms. It interacts with DNA by inserting itself between DNA base pairs (intercalation), which disrupts normal DNA function. The drug also inhibits topoisomerase II, stabilizing the DNA–topoisomerase II complex and preventing the repair of DNA strands. This results in both single-strand and double-strand DNA breaks. Additionally, Daunorubicin may inhibit DNA and RNA polymerase activity, alter gene expression, and produce free radicals that damage DNA. It has demonstrated strong antitumor activity against a wide range of experimental tumors in animal studies.

Distribution: Daunorubicin is rapidly and widely distributed throughout body tissues, with the highest concentrations found in the spleen, kidneys, liver, lungs, and heart. It binds strongly to cellular components, particularly nucleic acids. There is no clear evidence that it crosses the blood–brain barrier, but it can cross the placenta.

Metabolism and Elimination: Daunorubicin is extensively metabolized in the liver and other tissues, mainly through cytoplasmic aldo-keto reductase enzymes, producing its major active metabolite daunorubicinol. About 40% of the drug in plasma is converted to daunorubicinol within 30 minutes and about 60% within 4 hours after administration. Further metabolism occurs through reduction cleavage of the glycosidic bond, demethylation, and conjugation with sulfate and glucuronide. Around 25% of the administered dose is excreted unchanged in the urine, while approximately 40% is eliminated through bile.

Parenteral drug products should be inspected visually for particulate matter prior to administration.

Representative Dose Schedules and Combination for the Approved Indication of Remission Induction in Adult Acute Nonlymphocytic Leukemia: In Combination: For patients under age 60, Daunorubicin 45 mg/m2/day IV on days 1, 2, and 3 of the first course and on days 1, 2 of subsequent courses AND cytosine arabinoside 100 mg/m2/day IV infusion daily for 7 days for the first course and for 5 days for subsequent courses. For patients 60 years of age and above, Daunorubicin 30 mg/m2/day IV on days 1, 2, and 3 of the first course and on days 1, 2 of subsequent courses AND cytosine arabinoside 100 mg/m2/day IV infusion daily for 7 days for the first course and for 5 days for subsequent courses. This Daunorubicin dose-reduction is based on a single study and may not be appropriate if optimal supportive care is available.

Representative Dose Schedule and Combination for the Approved Indication of Remission Induction in Pediatric Acute Lymphocytic Leukemia: In Combination: Daunorubicin 25 mg/m2 IV on day 1 every week, Vincristine 1.5 mg/m2 IV on day 1 every week, prednisone 40 mg/m2 PO daily. Generally, a complete remission will be obtained within four such courses of therapy; however, if after four courses the patient is in partial remission, an additional one or, if necessary, two courses may be given in an effort to obtain a complete remission. In children less than 2 years of age or below 0.5 m2 body surface area, it has been recommended that the Daunorubicin dosage calculation should be based on weight (1 mg/kg) instead of body surface area.

Representative Dose Schedules and Combination for the Approved Indication of Remission Induction in Adult Acute Lymphocytic Leukemia: In Combination: Daunorubicin 45 mg/m2/day IV on days 1, 2, and 3 and Vincristine 2 mg IV on days 1, 8, and 15; prednisone 40 mg/m2/day PO on days 1 through 22, then tapered between days 22 to 29; L-asparaginase 500 IU/kg/day x 10 days IV on days 22 through 32. Or, as directed by the registered physicians.

Using Daunorubicin in patients who have previously received Doxorubicin may increase the risk of heart toxicity (cardiotoxicity). Therefore, Daunorubicin should not be given to patients who have already received the maximum recommended cumulative doses of either Doxorubicin or Daunorubicin. Concurrent use of Cyclophosphamide with Daunorubicin may further increase the risk of cardiotoxicity. When Daunorubicin is used together with other myelosuppressive drugs, a reduction in dosage may be necessary. Medicines that affect the liver, such as high-dose Methotrexate, may impair liver function and increase the risk of toxicity when used with Daunorubicin.

Daunorubicin is contraindicated in patients who have a known hypersensitivity or allergic reaction to Daunorubicin or any of the ingredients of the product.

The main dose-limiting toxicities of Daunorubicin are myelosuppression and cardiotoxicity. Other possible side effects include:

• Skin: Temporary hair loss (reversible alopecia) is common. Rare cases of rash, contact dermatitis, and urticaria may occur.
• Gastrointestinal: Nausea and vomiting may occur but are usually mild. Antiemetic medicines may help relieve these symptoms. Mouth sores (mucositis) may appear within 3–7 days after treatment. Diarrhea and abdominal pain have occasionally been reported.
• Local Reactions: If the drug leaks outside the vein during injection (extravasation), it may cause severe tissue damage, cellulitis, thrombophlebitis, or painful swelling.
• Acute Reactions: Rarely, allergic-like reactions such as fever, chills, or anaphylactoid reactions may occur. High uric acid levels (hyperuricemia) may develop, particularly in leukemia patients, so uric acid levels should be monitored.

Daunorubicin is classified as Pregnancy Category D, meaning it may cause harm to the unborn baby. It is not known whether Daunorubicin passes into human breast milk. Because many medicines can enter breast milk and may cause serious side effects in nursing infants, mothers are advised to stop breastfeeding during treatment with Daunorubicin.

Treatment with Daunorubicin requires careful monitoring. Patients should undergo regular complete blood count (CBC) tests, and their heart, liver, and kidney function should be evaluated before each treatment cycle. Any systemic infection should be treated before starting therapy. After administration, the drug may temporarily cause red discoloration of urine, which is expected and harmless.

Daunorubicin must be administered through a rapid intravenous infusion and should never be given by intramuscular or subcutaneous injection, as this can cause severe tissue damage.

Severe heart toxicity, including congestive heart failure, may occur during treatment or even months to years later. The risk increases when the cumulative dose exceeds 400–550 mg/m² in adults, 300 mg/m² in children over 2 years, or 10 mg/kg in children under 2 years.

Severe bone marrow suppression may occur with therapeutic doses, increasing the risk of infection and bleeding.

Daunorubicin should only be administered by physicians experienced in leukemia chemotherapy, in medical facilities equipped with laboratory monitoring and supportive care for managing severe complications.

Dose adjustments may be required in patients with impaired liver or kidney function.

Cytotoxic Chemotherapy

Store unopened vials in a refrigerator at 2–8°C. The product does not contain preservatives, so any unused portion should be discarded. Protect from light. If Daunorubicin comes into contact with the skin or mucous membranes, the affected area should be washed immediately with soap and water. Proper procedures for the handling and disposal of anticancer drugs should always be followed.